Zevra Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Zevra Therapeutics, Inc. (ZVRA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$4.38 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-10.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-08-10
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$494.00K.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$3.88M, a 108.62% decline year-over-year.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$4.08M.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$7.76M.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$15.56M, a 170.51% decline from fiscal 2015.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $22.06M, a 166.27% increase from fiscal 2014.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $8.29M.
- Zevra Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2013 was -$573.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2017-06-30 | -$494.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$4.38M 10-Q · filed 2017-08-10 | -$8.46M derived: sum of 3 quarters · filed 2017-08-10 | -$16.22M derived: sum of 4 quarters · filed 2017-08-10 | |
| 2017-03-31 | -$3.88M 10-Q · filed 2017-05-22 | -$7.97M derived: sum of 2 quarters · filed 2017-05-22 | -$15.73M derived: sum of 3 quarters · filed 2017-05-22 | -$64.45M derived: sum of 4 quarters · filed 2017-08-10 | |
| 2016-12-31 | -$4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$11.85M derived: sum of 2 quarters · filed 2017-03-10 | -$60.57M derived: sum of 3 quarters · filed 2017-08-10 | -$15.56M 10-K · filed 2017-03-10 | |
| 2016-09-30 | -$7.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$56.49M derived: sum of 2 quarters · filed 2017-08-10 | -$11.47M 10-Q · filed 2016-11-10 | -$38.16M derived: sum of 4 quarters · filed 2017-08-10 | |
| 2016-06-30 | -$48.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$3.71M 10-Q · filed 2017-08-10 | -$4.81M 10-Q · filed 2016-08-11 | -$30.40M derived: sum of 3 quarters · filed 2017-08-10 | -$35.61M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | $45.02M 10-Q · filed 2017-05-22 | $18.32M derived: sum of 2 quarters · filed 2017-05-22 | $13.11M derived: sum of 3 quarters · filed 2017-05-22 | $67.06M derived: sum of 4 quarters · filed 2017-05-22 | |
| 2015-12-31 | -$26.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$31.91M derived: sum of 2 quarters · filed 2017-03-10 | $22.05M derived: sum of 3 quarters · filed 2017-03-10 | $22.06M 10-K · filed 2017-03-10 | |
| 2015-09-30 | -$5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $48.74M derived: sum of 2 quarters · filed 2016-11-10 | $48.75M 10-Q · filed 2016-11-10 | $39.99M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-06-30 | $53.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $53.97M 10-Q · filed 2016-08-11 | $45.20M derived: sum of 3 quarters · filed 2017-03-10 | $41.27M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-03-31 | $14.00K 10-Q · filed 2016-05-13 | -$8.75M derived: sum of 2 quarters · filed 2017-03-10 | -$12.69M derived: sum of 3 quarters · filed 2017-03-10 | $9.21M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2014-12-31 | -$8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$12.70M derived: sum of 2 quarters · filed 2017-03-10 | $9.20M derived: sum of 3 quarters · filed 2017-03-10 | $8.29M 10-K · filed 2017-03-10 | |
| 2014-09-30 | -$3.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $17.97M derived: sum of 2 quarters · filed 2015-11-13 | $17.05M 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $21.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $20.99M 10-Q · filed 2015-08-14 | |||
| 2014-03-31 | -$914.00K 10-Q · filed 2015-05-29 | ||||
| 2013-12-31 | -$573.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |